Everything is cash pay - no insurance
This article provides a factual overview of all three compounds, their mechanisms, and how they compare based on published clinical trial data
Help consumers feel comfortable by reinforcing that its reasonable and responsible to consider GLP-1 treatment.
Currently available GLP-1 receptor agonists in the UK include: For type 2 diabetes : semaglutide (Ozempic [injection], Rybelsus [oral tablet]), dulaglutide (Trulicity), liraglutide (Victoza), exenatide (Byetta, Bydureon), and lixisenatide (Lyxumia) For weight management : semaglutide 2.4 mg (Wegovy) and liraglutide 3 mg (Saxenda) Most GLP-1 medications are administered via subcutaneous injection, with dosing frequencies ranging from daily to once weekly depending on the specific formulation
The grouping makes no combined-effect claim and is supplied strictly for in-vitro laboratory research use only.
But with their rise in popularity comes important questions about potential side effects